VIR - JPMorgan likes Qiagen in premarket analyst action November, 14 2019 08:56 AM Vir Biotechnology Inc. Arvinas (NASDAQ:ARVN) initiated with Buy rating and $35 (23% upside) price target at Roth Capital.More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...